Mergers and Acquisitions

Evonik will acquire Transferra for an undisclosed amount, and the transaction is scheduled to close at the end of July 2016

Charles River acquired Blue Stream Laboratories, an analytical contract research organization.

Merck will acquire Afferent Pharmaceuticals for $500 million in cash with the potential for additional payments.

Jazz will acquire Celator for approximately $1.5 billion.

Pfizer will acquire Anacor for $5.2 billion and expects the transaction to complete in the third-quarter of 2016.

The companies have agreed to an all-stock merger of equals transaction anticipated to close in the second half of 2016.

AbbVie will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), a novel biomarker-specific therapy derived from cancer stem cells.

The companies announced that they have mutually decided to terminate the planned merger after the US Department of Treasury and the IRS issue temporary and proposed regulations on tax inversion.

The companies will merge to create a gene therapy biologics CDMO.

The companies say the acquisition will assist in expediting the clinical development of RhoNova, a potential treatment targeting rhodopsin-linked autosomal dominant retinitis pigmentosa.

Unchained Labs acquires Freeslate, marking the company’s fourth acquisition in the past 12 months.

Novartis announced on Jan. 5, 2016 that the company is collaborating with Qualcomm to develop cloud-based technology for COPD patients.

Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.

Charles River Laboratories entered into a definitive agreement to acquire WIL Research.

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016.

GlaxoSmithKline acquires Bristol-Meyers Squibb’s late-stage HIV R&D assets.

Charles River Laboratories announces the acquisition of Oncotest GmbH.

As a result of the acquisition, Merck will have access to Harrisvaccine’s proprietary RNA Particle technology production platform.

AstraZeneca has agreed to acquire ZS Pharma for $2.7 billion, according to a press release from AstraZeneca. 

Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.

The acquisition will give IDT Biologika access to the veterinary vaccines market.

Charles Rivers strengthens its endotoxin testing and bacterial identification detection capabilities with the addition of Celsis’ products.

According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development.

Kythera announces that it entered into a definitive agreement to be acquired by Allergan for $2.1 billion.